



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 15, 2018

Jason B. Shandell  
President  
Amphastar Pharmaceuticals, Inc.  
11570 6th Street  
Rancho Cucamonga, CA 91730

**Re: Amphastar Pharmaceuticals, Inc.  
Registration Statement on Form S-3  
Filed November 9, 2018  
File No. 333-228318**

Dear Mr. Shandell:

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jeffrey Gabor at 202-551-2544 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Andrew D. Hoffman, Esq.